Nutriband Inc (NASDAQ: NTRB) is a pharmaceutical company that develops and manufactures transdermal drug delivery products. Revenue comes primarily from product sales through its Pocono Pharmaceuticals segment, which manufactures transdermal tapes and patches, with a secondary segment, 4P Therapeutics, focused on contract research and development services that generated no revenue in FY2026. Total revenue was $2,036,651 for the year ended January 31, 2026, down from $2,139,537 in the year ended January 31, 2025, with gross profit of $566,308 (FY2026) versus $743,317 (FY2025). The decline in gross profit reflected lower margins on tape sales. SG&A expenses of $6,993,140 in FY2026 far exceeded gross profit, and the company carried a net loss from operations for the period. As of January 31, 2026, Nutriband held $4,574,857 in cash and working capital of $4,204,632. Its pipeline includes AVERSA Fentanyl and AVERSA Buprenorphine, abuse-deterrent transdermal opioid products pending regulatory approval. CEO Gareth Sheridan leads the company.

Revenue model

Transactional product sales from the Pocono Pharmaceuticals segment (transdermal tapes and patches). The 4P Therapeutics segment previously generated contract research and development service revenue but recorded $0 in FY2026 after its main contract wound down.

Products and services

Transdermal pharmaceutical tapes and patches manufactured by Pocono Pharmaceuticals. Pipeline products include AVERSA Fentanyl and AVERSA Buprenorphine, abuse-deterrent transdermal opioid formulations pending FDA approval. 4P Therapeutics LLC provides contract pharmaceutical research and development services.

Customers and end markets

The filing does not disclose specific customer names, customer concentration data, or end-market breakdowns beyond the pharmaceutical and transdermal drug delivery sector.

Value-chain role

Manufacturer and developer of transdermal drug delivery products. Pocono Pharmaceuticals handles physical manufacturing; 4P Therapeutics handles contract R&D. The company originates its own pipeline products and pursues regulatory approval independently.

Geographic exposure

The filing identifies the company as U.S.-based and references the U.S. opioid market as the primary target for its AVERSA pipeline products. No international revenue breakdown is disclosed.

Source: SEC 10-K, filed 2026-04-29

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: Talphera Inc Elicio Therapeutics Inc Real Brands, Inc. Clever Leaves Holdings Inc. Elite Pharmaceuticals Inc Processa Pharmaceuticals Inc Johnson & Johnson NVN Liquidation, Inc. Reviva Pharmaceuticals Holdings Inc